Skip to main content

Rydym wedi cadw rhai ffeiliau o'r enw cwcis ar eich dyfais. Y cwcis hyn yw:

  • Hanfodol ar gyfer y safle i weithio
  • Helpu i wella ein gwefan drwy gasglu ac adrodd gwybodaeth am sut rydych chi'n ei defnyddio

Hoffem hefyd arbed rhai cwcis i helpu i deilwra cyfathrebu.

BETA
Rydych yn edrych ar fersiwn wedi'i ddiweddaru o'r gwasanaeth hwn - bydd eich adborth yn ein helpu i'w wella.

Hysbysiad o Gontract

Generic and Biosimilar Cancer Medicines

  • Cyhoeddwyd gyntaf: 17 Medi 2022
  • Wedi'i addasu ddiwethaf: 17 Medi 2022

Nid yw'r prynwr yn defnyddio'r wefan hon i weinyddu'r hysbysiad.

I gofnodi eich diddordeb neu gael gwybodaeth neu ddogfennau ychwanegol, darllenwch y cyfarwyddiadau yn Nhestun Llawn yr Hysbysiad. (NODER: Nid oes angen ymateb i Hysbysiadau Dyfarnu Contractau a Hysbysiadau Gwybodaeth Ymlaen Llaw fel arfer)

Cynnwys

Crynodeb

OCID:
ocds-h6vhtk-0368ee
Cyhoeddwyd gan:
The Common Services Agency (more commonly known as NHS National Services Scotland) ("the Authority")
ID Awudurdod:
AA80495
Dyddiad cyhoeddi:
17 Medi 2022
Dyddiad Cau:
17 Hydref 2022
Math o hysbysiad:
Hysbysiad o Gontract
Mae ganddo ddogfennau:
Nac Ydi
Wedi SPD:
Nac Ydi
Mae ganddo gynllun lleihau carbon:
AMH

Crynodeb

Supply of Bendamustine Powder For Solution For Infusion to NHS Scotland. The Authority intends awarding all presentations within this lot to a single supplier. Full details can be found within the ITT.

Testun llawn y rhybydd

Hysbysiad contract

Adran I: Endid contractio

I.1) Enw a chyfeiriad

The Common Services Agency (more commonly known as NHS National Services Scotland) ("the Authority")

Gyle Square (NSS Head Office), 1 South Gyle Crescent

Edinburgh

EH12 9EB

UK

Person cyswllt: Linda Downie

Ffôn: +44 1698794410

E-bost: Linda.Downie3@nhs.scot

NUTS: UKM

Cyfeiriad(au) rhyngrwyd

Prif gyfeiriad: http://www.nhsscotlandprocurement.scot.nhs.uk/

Cyfeiriad proffil y prynwr: http://www.publiccontractsscotland.gov.uk/search/Search_AuthProfile.aspx?ID=AA11883

I.2) Caffael ar y cyd

Caiff y contract ei ddyfarnu gan gorff prynu canolog

I.3) Cyfathrebu

Mae'r dogfennau caffael ar gael ar gyfer mynediad uniongyrchol anghyfyngedig a llawn, yn rhad ac am ddim ar:

https://www.publictendersscotland.publiccontractsscotland.gov.uk/web/login.html


Gellir cael gwybodaeth ychwanegol o'r cyfeiriad uchod


Rhaid anfon tendrau neu geisiadau i gymryd rhan yn electronig at:

https://www.publictendersscotland.publiccontractsscotland.gov.uk/web/login.html


I.4) Y math o awdurdod contractio

Corff a lywodraethir gan gyfraith gyhoeddus

I.5) Prif weithgaredd

Iechyd

Adran II: Gwrthrych

II.1) Cwmpas y caffaeliad

II.1.1) Teitl

Generic and Biosimilar Cancer Medicines

Cyfeirnod: NP39722

II.1.2) Prif god CPV

33600000

 

II.1.3) Y math o gontract

Cyflenwadau

II.1.4) Disgrifiad byr

This Framework Agreement is for the supply of generic and biosimilar cancer medicines to NHS Scotland.

The Goods have been separated into forty-one (41) categories, each of which is identified as a “Lot”.

Full details of each Lot is contained in section II.2 of this Notice.

II.1.5) Cyfanswm gwerth amcangyfrifedig

Gwerth heb gynnwys TAW: 59 145 973.00 GBP

II.1.6) Gwybodaeth am lotiau

Mae’r contract hwn wedi’i rannu’n lotiau: Ydy

Gellir cyflwyno tendrau ar gyfer pob lot

II.2) Disgrifiad

Rhif y Lot 1

II.2.1) Teitl

Lot 1 Bendamustine Powder For Solution For Infusion

II.2.2) Cod(au) CPV ychwanegol

33600000

II.2.3) Man cyflawni

Cod NUTS:

UKM


Prif safle neu fan cyflawni:

All entities constituted pursuant to the National Health Services (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to New Public Bodies (Joint Working) Scotland Act 2014.

II.2.4) Disgrifiad o’r caffaeliad

Supply of Bendamustine Powder For Solution For Infusion to NHS Scotland. The Authority intends awarding all presentations within this lot to a single supplier. Full details can be found within the ITT.

II.2.5) Meini prawf dyfarnu

Maen prawf isod:

Maes prawf ansawdd: Logistics / Pwysoliad: 5

Price / Pwysoliad:  95

II.2.6) Gwerth amcangyfrifedig

Gwerth heb gynnwys TAW: 94 841.00 GBP

II.2.7) Hyd y contract, y cytundeb fframwaith neu’r system brynu ddynamig

Hyd mewn misoedd: 24

Gall y contract hwn gael ei adnewyddu: Ydy

Disgrifiad o’r adnewyddiadau:

The Authority is entitled at its sole discretion to extend the Framework Agreement for up to a maximum of twenty four (24) months by giving a minimum of three (3) months written notice of such extension(s).

II.2.9) Gwybodaeth am y cyfyngiadau ar nifer yr ymgeiswyr a gaiff eu gwahodd

II.2.10) Gwybodaeth am amrywiadau

Derbynnir amrywiadau: Na

II.2.11) Gwybodaeth am opsiynau

Opsiynau: Na

II.2.13) Gwybodaeth am Gronfeydd yr Undeb Ewropeaidd

Mae'r broses gaffael yn gysylltiedig â phrosiect a/neu raglen a ariennir gan gronfeydd yr Undeb Ewropeaidd: Na

Rhif y Lot 2

II.2.1) Teitl

Lot 2 Capecitabine Tablets

II.2.2) Cod(au) CPV ychwanegol

33600000

II.2.3) Man cyflawni

Cod NUTS:

UKM


Prif safle neu fan cyflawni:

All entities constituted pursuant to the National Health Services (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to New Public Bodies (Joint Working) Scotland Act 2014.

II.2.4) Disgrifiad o’r caffaeliad

Supply of Capecitabine Tablets to NHS Scotland. The Authority intends awarding all presentations within this lot to a single supplier. Full details can be found within the ITT.

II.2.5) Meini prawf dyfarnu

Maen prawf isod:

Maes prawf ansawdd: Logistics / Pwysoliad: 5

Price / Pwysoliad:  95

II.2.6) Gwerth amcangyfrifedig

Gwerth heb gynnwys TAW: 910 974.00 GBP

II.2.7) Hyd y contract, y cytundeb fframwaith neu’r system brynu ddynamig

Hyd mewn misoedd: 24

Gall y contract hwn gael ei adnewyddu: Ydy

Disgrifiad o’r adnewyddiadau:

The Authority is entitled at its sole discretion to extend the Framework Agreement for up to a maximum of twenty four (24) months by giving a minimum of three (3) months written notice of such extension(s).

II.2.9) Gwybodaeth am y cyfyngiadau ar nifer yr ymgeiswyr a gaiff eu gwahodd

II.2.10) Gwybodaeth am amrywiadau

Derbynnir amrywiadau: Na

II.2.11) Gwybodaeth am opsiynau

Opsiynau: Na

II.2.13) Gwybodaeth am Gronfeydd yr Undeb Ewropeaidd

Mae'r broses gaffael yn gysylltiedig â phrosiect a/neu raglen a ariennir gan gronfeydd yr Undeb Ewropeaidd: Na

Rhif y Lot 3

II.2.1) Teitl

Lot 3 Carboplatin Injection

II.2.2) Cod(au) CPV ychwanegol

33600000

II.2.3) Man cyflawni

Cod NUTS:

UKM


Prif safle neu fan cyflawni:

All entities constituted pursuant to the National Health Services (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to New Public Bodies (Joint Working) Scotland Act 2014.

II.2.4) Disgrifiad o’r caffaeliad

Supply of Carboplatin Injections to NHS Scotland. The Authority intends awarding all presentations within this lot to a single supplier. Full details can be found within the ITT.

II.2.5) Meini prawf dyfarnu

Maen prawf isod:

Maes prawf ansawdd: Logistics / Pwysoliad: 5

Price / Pwysoliad:  95

II.2.6) Gwerth amcangyfrifedig

Gwerth heb gynnwys TAW: 596 546.00 GBP

II.2.7) Hyd y contract, y cytundeb fframwaith neu’r system brynu ddynamig

Hyd mewn misoedd: 24

Gall y contract hwn gael ei adnewyddu: Ydy

Disgrifiad o’r adnewyddiadau:

The Authority is entitled at its sole discretion to extend the Framework Agreement for up to a maximum of twenty four (24) months by giving a minimum of three (3) months written notice of such extension(s).

II.2.9) Gwybodaeth am y cyfyngiadau ar nifer yr ymgeiswyr a gaiff eu gwahodd

II.2.10) Gwybodaeth am amrywiadau

Derbynnir amrywiadau: Na

II.2.11) Gwybodaeth am opsiynau

Opsiynau: Na

II.2.13) Gwybodaeth am Gronfeydd yr Undeb Ewropeaidd

Mae'r broses gaffael yn gysylltiedig â phrosiect a/neu raglen a ariennir gan gronfeydd yr Undeb Ewropeaidd: Na

Rhif y Lot 4

II.2.1) Teitl

Lot 4 Cisplatin Injection

II.2.2) Cod(au) CPV ychwanegol

33600000

II.2.3) Man cyflawni

Cod NUTS:

UKM


Prif safle neu fan cyflawni:

All entities constituted pursuant to the National Health Services (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to New Public Bodies (Joint Working) Scotland Act 2014.

II.2.4) Disgrifiad o’r caffaeliad

Supply of Cisplatin Injections to NHS Scotland. The Authority intends awarding all presentations within this lot to a single supplier. Full details can be found within the ITT.

II.2.5) Meini prawf dyfarnu

Maen prawf isod:

Maes prawf ansawdd: Logistics / Pwysoliad: 5

Price / Pwysoliad:  95

II.2.6) Gwerth amcangyfrifedig

Gwerth heb gynnwys TAW: 186 020.00 GBP

II.2.7) Hyd y contract, y cytundeb fframwaith neu’r system brynu ddynamig

Hyd mewn misoedd: 24

Gall y contract hwn gael ei adnewyddu: Ydy

Disgrifiad o’r adnewyddiadau:

The Authority is entitled at its sole discretion to extend the Framework Agreement for up to a maximum of twenty four (24) months by giving a minimum of three (3) months written notice of such extension(s).

II.2.9) Gwybodaeth am y cyfyngiadau ar nifer yr ymgeiswyr a gaiff eu gwahodd

II.2.10) Gwybodaeth am amrywiadau

Derbynnir amrywiadau: Na

II.2.11) Gwybodaeth am opsiynau

Opsiynau: Na

II.2.13) Gwybodaeth am Gronfeydd yr Undeb Ewropeaidd

Mae'r broses gaffael yn gysylltiedig â phrosiect a/neu raglen a ariennir gan gronfeydd yr Undeb Ewropeaidd: Na

Rhif y Lot 5

II.2.1) Teitl

Lot 5 Cyclophosphamide Injection, Powder For Reconstitution

II.2.2) Cod(au) CPV ychwanegol

33600000

II.2.3) Man cyflawni

Cod NUTS:

UKM


Prif safle neu fan cyflawni:

All entities constituted pursuant to the National Health Services (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to New Public Bodies (Joint Working) Scotland Act 2014.

II.2.4) Disgrifiad o’r caffaeliad

Supply of Cyclophosphamide Injection, Powder For Reconstitution to NHS Scotland. The Authority intends awarding all presentations within this lot to a single supplier. Full details can be found within the ITT.

II.2.5) Meini prawf dyfarnu

Maen prawf isod:

Maes prawf ansawdd: Logistics / Pwysoliad: 5

Price / Pwysoliad:  95

II.2.6) Gwerth amcangyfrifedig

Gwerth heb gynnwys TAW: 267 442.00 GBP

II.2.7) Hyd y contract, y cytundeb fframwaith neu’r system brynu ddynamig

Hyd mewn misoedd: 24

Gall y contract hwn gael ei adnewyddu: Ydy

Disgrifiad o’r adnewyddiadau:

The Authority is entitled at its sole discretion to extend the Framework Agreement for up to a maximum of twenty four (24) months by giving a minimum of three (3) months written notice of such extension(s).

II.2.9) Gwybodaeth am y cyfyngiadau ar nifer yr ymgeiswyr a gaiff eu gwahodd

II.2.10) Gwybodaeth am amrywiadau

Derbynnir amrywiadau: Na

II.2.11) Gwybodaeth am opsiynau

Opsiynau: Na

II.2.13) Gwybodaeth am Gronfeydd yr Undeb Ewropeaidd

Mae'r broses gaffael yn gysylltiedig â phrosiect a/neu raglen a ariennir gan gronfeydd yr Undeb Ewropeaidd: Na

Rhif y Lot 6

II.2.1) Teitl

Lot 6 Cytarabine Injections

II.2.2) Cod(au) CPV ychwanegol

33600000

II.2.3) Man cyflawni

Cod NUTS:

UKM


Prif safle neu fan cyflawni:

All entities constituted pursuant to the National Health Services (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to New Public Bodies (Joint Working) Scotland Act 2014.

II.2.4) Disgrifiad o’r caffaeliad

Supply of Cytarabine Injections to NHS Scotland. The Authority intends awarding all presentations within this lot to a single supplier. Full details can be found within the ITT.

II.2.5) Meini prawf dyfarnu

Maen prawf isod:

Maes prawf ansawdd: Logistics / Pwysoliad: 5

Price / Pwysoliad:  95

II.2.6) Gwerth amcangyfrifedig

Gwerth heb gynnwys TAW: 104 724.00 GBP

II.2.7) Hyd y contract, y cytundeb fframwaith neu’r system brynu ddynamig

Hyd mewn misoedd: 24

Gall y contract hwn gael ei adnewyddu: Ydy

Disgrifiad o’r adnewyddiadau:

The Authority is entitled at its sole discretion to extend the Framework Agreement for up to a maximum of twenty four (24) months by giving a minimum of three (3) months written notice of such extension(s).

II.2.9) Gwybodaeth am y cyfyngiadau ar nifer yr ymgeiswyr a gaiff eu gwahodd

II.2.10) Gwybodaeth am amrywiadau

Derbynnir amrywiadau: Na

II.2.11) Gwybodaeth am opsiynau

Opsiynau: Na

II.2.13) Gwybodaeth am Gronfeydd yr Undeb Ewropeaidd

Mae'r broses gaffael yn gysylltiedig â phrosiect a/neu raglen a ariennir gan gronfeydd yr Undeb Ewropeaidd: Na

Rhif y Lot 7

II.2.1) Teitl

Lot 7 Dacarbazine Injections

II.2.2) Cod(au) CPV ychwanegol

33600000

II.2.3) Man cyflawni

Cod NUTS:

UKM


Prif safle neu fan cyflawni:

All entities constituted pursuant to the National Health Services (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to New Public Bodies (Joint Working) Scotland Act 2014.

II.2.4) Disgrifiad o’r caffaeliad

Supply of Dacarbazine Injections to NHS Scotland. The Authority intends awarding all presentations within this lot to a single supplier. Full details can be found within the ITT.

II.2.5) Meini prawf dyfarnu

Maen prawf isod:

Maes prawf ansawdd: Logistics / Pwysoliad: 5

Price / Pwysoliad:  95

II.2.6) Gwerth amcangyfrifedig

Gwerth heb gynnwys TAW: 592 972.00 GBP

II.2.7) Hyd y contract, y cytundeb fframwaith neu’r system brynu ddynamig

Hyd mewn misoedd: 24

Gall y contract hwn gael ei adnewyddu: Ydy

Disgrifiad o’r adnewyddiadau:

The Authority is entitled at its sole discretion to extend the Framework Agreement for up to a maximum of twenty four (24) months by giving a minimum of three (3) months written notice of such extension(s).

II.2.9) Gwybodaeth am y cyfyngiadau ar nifer yr ymgeiswyr a gaiff eu gwahodd

II.2.10) Gwybodaeth am amrywiadau

Derbynnir amrywiadau: Na

II.2.11) Gwybodaeth am opsiynau

Opsiynau: Na

II.2.13) Gwybodaeth am Gronfeydd yr Undeb Ewropeaidd

Mae'r broses gaffael yn gysylltiedig â phrosiect a/neu raglen a ariennir gan gronfeydd yr Undeb Ewropeaidd: Na

Rhif y Lot 8

II.2.1) Teitl

Lot 8 Disodium Folinate Injection

II.2.2) Cod(au) CPV ychwanegol

33600000

II.2.3) Man cyflawni

Cod NUTS:

UKM


Prif safle neu fan cyflawni:

All entities constituted pursuant to the National Health Services (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to New Public Bodies (Joint Working) Scotland Act 2014.

II.2.4) Disgrifiad o’r caffaeliad

Supply of Disodium Folinate Injections to NHS Scotland. The Authority intends awarding all presentations within this lot to a single supplier. Full details can be found within the ITT.

II.2.5) Meini prawf dyfarnu

Maen prawf isod:

Maes prawf ansawdd: Logistics / Pwysoliad: 5

Price / Pwysoliad:  95

II.2.6) Gwerth amcangyfrifedig

Gwerth heb gynnwys TAW: 442 064.00 GBP

II.2.7) Hyd y contract, y cytundeb fframwaith neu’r system brynu ddynamig

Hyd mewn misoedd: 24

Gall y contract hwn gael ei adnewyddu: Ydy

Disgrifiad o’r adnewyddiadau:

The Authority is entitled at its sole discretion to extend the Framework Agreement for up to a maximum of twenty four (24) months by giving a minimum of three (3) months written notice of such extension(s).

II.2.9) Gwybodaeth am y cyfyngiadau ar nifer yr ymgeiswyr a gaiff eu gwahodd

II.2.10) Gwybodaeth am amrywiadau

Derbynnir amrywiadau: Na

II.2.11) Gwybodaeth am opsiynau

Opsiynau: Na

II.2.13) Gwybodaeth am Gronfeydd yr Undeb Ewropeaidd

Mae'r broses gaffael yn gysylltiedig â phrosiect a/neu raglen a ariennir gan gronfeydd yr Undeb Ewropeaidd: Na

Rhif y Lot 9

II.2.1) Teitl

Lot 9 Docetaxel Concentrate For Solution For Infusion

II.2.2) Cod(au) CPV ychwanegol

33600000

II.2.3) Man cyflawni

Cod NUTS:

UKM


Prif safle neu fan cyflawni:

All entities constituted pursuant to the National Health Services (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to New Public Bodies (Joint Working) Scotland Act 2014.

II.2.4) Disgrifiad o’r caffaeliad

Supply of Docetaxel Concentrate For Solution For Infusion to NHS Scotland. The Authority intends awarding all presentations within this lot to a single supplier. Full details can be found within the ITT.

II.2.5) Meini prawf dyfarnu

Maen prawf isod:

Maes prawf ansawdd: Logistics / Pwysoliad: 5

Price / Pwysoliad:  95

II.2.6) Gwerth amcangyfrifedig

Gwerth heb gynnwys TAW: 333 456.00 GBP

II.2.7) Hyd y contract, y cytundeb fframwaith neu’r system brynu ddynamig

Hyd mewn misoedd: 24

Gall y contract hwn gael ei adnewyddu: Ydy

Disgrifiad o’r adnewyddiadau:

The Authority is entitled at its sole discretion to extend the Framework Agreement for up to a maximum of twenty four (24) months by giving a minimum of three (3) months written notice of such extension(s).

II.2.9) Gwybodaeth am y cyfyngiadau ar nifer yr ymgeiswyr a gaiff eu gwahodd

II.2.10) Gwybodaeth am amrywiadau

Derbynnir amrywiadau: Na

II.2.11) Gwybodaeth am opsiynau

Opsiynau: Na

II.2.13) Gwybodaeth am Gronfeydd yr Undeb Ewropeaidd

Mae'r broses gaffael yn gysylltiedig â phrosiect a/neu raglen a ariennir gan gronfeydd yr Undeb Ewropeaidd: Na

Rhif y Lot 10

II.2.1) Teitl

Lot 10 Doxorubicin Hydrochloride Injections

II.2.2) Cod(au) CPV ychwanegol

33600000

II.2.3) Man cyflawni

Cod NUTS:

UKM


Prif safle neu fan cyflawni:

All entities constituted pursuant to the National Health Services (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to New Public Bodies (Joint Working) Scotland Act 2014

II.2.4) Disgrifiad o’r caffaeliad

Supply of Doxorubicin Hydrochloride Injections to NHS Scotland. The Authority intends awarding all presentations within this lot to a single supplier. Full details can be found within the ITT.

II.2.5) Meini prawf dyfarnu

Maen prawf isod:

Maes prawf ansawdd: Logistics / Pwysoliad: 5

Price / Pwysoliad:  95

II.2.6) Gwerth amcangyfrifedig

Gwerth heb gynnwys TAW: 60 002.00 GBP

II.2.7) Hyd y contract, y cytundeb fframwaith neu’r system brynu ddynamig

Hyd mewn misoedd: 24

Gall y contract hwn gael ei adnewyddu: Ydy

Disgrifiad o’r adnewyddiadau:

The Authority is entitled at its sole discretion to extend the Framework Agreement for up to a maximum of twenty four (24) months by giving a minimum of three (3) months written notice of such extension(s).

II.2.9) Gwybodaeth am y cyfyngiadau ar nifer yr ymgeiswyr a gaiff eu gwahodd

II.2.10) Gwybodaeth am amrywiadau

Derbynnir amrywiadau: Na

II.2.11) Gwybodaeth am opsiynau

Opsiynau: Na

II.2.13) Gwybodaeth am Gronfeydd yr Undeb Ewropeaidd

Mae'r broses gaffael yn gysylltiedig â phrosiect a/neu raglen a ariennir gan gronfeydd yr Undeb Ewropeaidd: Na

Rhif y Lot 11

II.2.1) Teitl

Lot 11 Fluorouracil 25MG/ML Injection

II.2.2) Cod(au) CPV ychwanegol

33600000

II.2.3) Man cyflawni

Cod NUTS:

UKM


Prif safle neu fan cyflawni:

All entities constituted pursuant to the National Health Services (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to New Public Bodies (Joint Working) Scotland Act 2014.

II.2.4) Disgrifiad o’r caffaeliad

Supply of Fluorouracil 25MG/ML Injections to NHS Scotland. The Authority intends awarding all presentations within this lot to a single supplier. Full details can be found within the ITT.

II.2.5) Meini prawf dyfarnu

Maen prawf isod:

Maes prawf ansawdd: Logistics / Pwysoliad: 5

Price / Pwysoliad:  95

II.2.6) Gwerth amcangyfrifedig

Gwerth heb gynnwys TAW: 44 750.00 GBP

II.2.7) Hyd y contract, y cytundeb fframwaith neu’r system brynu ddynamig

Hyd mewn misoedd: 24

Gall y contract hwn gael ei adnewyddu: Ydy

Disgrifiad o’r adnewyddiadau:

The Authority is entitled at its sole discretion to extend the Framework Agreement for up to a maximum of twenty four (24) months by giving a minimum of three (3) months written notice of such extension(s).

II.2.9) Gwybodaeth am y cyfyngiadau ar nifer yr ymgeiswyr a gaiff eu gwahodd

II.2.10) Gwybodaeth am amrywiadau

Derbynnir amrywiadau: Na

II.2.11) Gwybodaeth am opsiynau

Opsiynau: Na

II.2.13) Gwybodaeth am Gronfeydd yr Undeb Ewropeaidd

Mae'r broses gaffael yn gysylltiedig â phrosiect a/neu raglen a ariennir gan gronfeydd yr Undeb Ewropeaidd: Na

Rhif y Lot 12

II.2.1) Teitl

Lot 12 Fluorouracil 50MG/ML Injection

II.2.2) Cod(au) CPV ychwanegol

33600000

II.2.3) Man cyflawni

Cod NUTS:

UKM


Prif safle neu fan cyflawni:

All entities constituted pursuant to the National Health Services (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to New Public Bodies (Joint Working) Scotland Act 2014

II.2.4) Disgrifiad o’r caffaeliad

Supply of Fluorouracil 50MG/ML Injections to NHS Scotland. The Authority intends awarding all presentations within this lot to a single supplier. Full details can be found within the ITT.

II.2.5) Meini prawf dyfarnu

Maen prawf isod:

Maes prawf ansawdd: Logistics / Pwysoliad: 5

Price / Pwysoliad:  95

II.2.6) Gwerth amcangyfrifedig

Gwerth heb gynnwys TAW: 236 261.00 GBP

II.2.7) Hyd y contract, y cytundeb fframwaith neu’r system brynu ddynamig

Hyd mewn misoedd: 24

Gall y contract hwn gael ei adnewyddu: Ydy

Disgrifiad o’r adnewyddiadau:

The Authority is entitled at its sole discretion to extend the Framework Agreement for up to a maximum of twenty four (24) months by giving a minimum of three (3) months written notice of such extension(s).

II.2.9) Gwybodaeth am y cyfyngiadau ar nifer yr ymgeiswyr a gaiff eu gwahodd

II.2.10) Gwybodaeth am amrywiadau

Derbynnir amrywiadau: Na

II.2.11) Gwybodaeth am opsiynau

Opsiynau: Na

II.2.13) Gwybodaeth am Gronfeydd yr Undeb Ewropeaidd

Mae'r broses gaffael yn gysylltiedig â phrosiect a/neu raglen a ariennir gan gronfeydd yr Undeb Ewropeaidd: Na

Rhif y Lot 13

II.2.1) Teitl

Lot 13 Gemcitabine 38MG/ML Concentrate For Solution For Infusion Vials

II.2.2) Cod(au) CPV ychwanegol

33600000

II.2.3) Man cyflawni

Cod NUTS:

UKM


Prif safle neu fan cyflawni:

All entities constituted pursuant to the National Health Services (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to New Public Bodies (Joint Working) Scotland Act 2014

II.2.4) Disgrifiad o’r caffaeliad

Supply of Gemcitabine 38MG/ML Concentrate For Solution For Infusion Vials to NHS Scotland. The Authority intends awarding all presentations within this lot to a single supplier. Full details can be found within the ITT.

II.2.5) Meini prawf dyfarnu

Maen prawf isod:

Maes prawf ansawdd: Logistics / Pwysoliad: 5

Price / Pwysoliad:  95

II.2.6) Gwerth amcangyfrifedig

Gwerth heb gynnwys TAW: 108 791.00 GBP

II.2.7) Hyd y contract, y cytundeb fframwaith neu’r system brynu ddynamig

Hyd mewn misoedd: 24

Gall y contract hwn gael ei adnewyddu: Ydy

Disgrifiad o’r adnewyddiadau:

The Authority is entitled at its sole discretion to extend the Framework Agreement for up to a maximum of twenty four (24) months by giving a minimum of three (3) months written notice of such extension(s).

II.2.9) Gwybodaeth am y cyfyngiadau ar nifer yr ymgeiswyr a gaiff eu gwahodd

II.2.10) Gwybodaeth am amrywiadau

Derbynnir amrywiadau: Na

II.2.11) Gwybodaeth am opsiynau

Opsiynau: Na

II.2.13) Gwybodaeth am Gronfeydd yr Undeb Ewropeaidd

Mae'r broses gaffael yn gysylltiedig â phrosiect a/neu raglen a ariennir gan gronfeydd yr Undeb Ewropeaidd: Na

Rhif y Lot 14

II.2.1) Teitl

Lot 14 Gemcitabine 100MG/ML Concentrate For Solution For Infusion Vials

II.2.2) Cod(au) CPV ychwanegol

33600000

II.2.3) Man cyflawni

Cod NUTS:

UKM


Prif safle neu fan cyflawni:

All entities constituted pursuant to the National Health Services (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to New Public Bodies (Joint Working) Scotland Act 2014

II.2.4) Disgrifiad o’r caffaeliad

Supply of Gemcitabine 100MG/ML Concentrate For Solution For Infusion Vials to NHS Scotland. The Authority intends awarding all presentations within this lot to a single supplier. Full details can be found within the ITT.

II.2.5) Meini prawf dyfarnu

Maen prawf isod:

Maes prawf ansawdd: Logistics / Pwysoliad: 5

Price / Pwysoliad:  95

II.2.6) Gwerth amcangyfrifedig

Gwerth heb gynnwys TAW: 18 031.00 GBP

II.2.7) Hyd y contract, y cytundeb fframwaith neu’r system brynu ddynamig

Hyd mewn misoedd: 24

Gall y contract hwn gael ei adnewyddu: Ydy

Disgrifiad o’r adnewyddiadau:

The Authority is entitled at its sole discretion to extend the Framework Agreement for up to a maximum of twenty four (24) months by giving a minimum of three (3) months written notice of such extension(s).

II.2.9) Gwybodaeth am y cyfyngiadau ar nifer yr ymgeiswyr a gaiff eu gwahodd

II.2.10) Gwybodaeth am amrywiadau

Derbynnir amrywiadau: Na

II.2.11) Gwybodaeth am opsiynau

Opsiynau: Na

II.2.13) Gwybodaeth am Gronfeydd yr Undeb Ewropeaidd

Mae'r broses gaffael yn gysylltiedig â phrosiect a/neu raglen a ariennir gan gronfeydd yr Undeb Ewropeaidd: Na

Rhif y Lot 15

II.2.1) Teitl

Lot 15 Gemcitabine Powder For Solution For Infusion Vials

II.2.2) Cod(au) CPV ychwanegol

33600000

II.2.3) Man cyflawni

Cod NUTS:

UKM


Prif safle neu fan cyflawni:

All entities constituted pursuant to the National Health Services (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to New Public Bodies (Joint Working) Scotland Act 2014

II.2.4) Disgrifiad o’r caffaeliad

Supply of Gemcitabine Powder For Solution For Infusion Vials to NHS Scotland. The Authority intends awarding all presentations within this lot to a single supplier. Full details can be found within the ITT.

II.2.5) Meini prawf dyfarnu

Maen prawf isod:

Maes prawf ansawdd: Logistics / Pwysoliad: 5

Price / Pwysoliad:  95

II.2.6) Gwerth amcangyfrifedig

Gwerth heb gynnwys TAW: 125 603.00 GBP

II.2.7) Hyd y contract, y cytundeb fframwaith neu’r system brynu ddynamig

Hyd mewn misoedd: 24

Gall y contract hwn gael ei adnewyddu: Ydy

Disgrifiad o’r adnewyddiadau:

The Authority is entitled at its sole discretion to extend the Framework Agreement for up to a maximum of twenty four (24) months by giving a minimum of three (3) months written notice of such extension(s).

II.2.9) Gwybodaeth am y cyfyngiadau ar nifer yr ymgeiswyr a gaiff eu gwahodd

II.2.10) Gwybodaeth am amrywiadau

Derbynnir amrywiadau: Na

II.2.11) Gwybodaeth am opsiynau

Opsiynau: Na

II.2.13) Gwybodaeth am Gronfeydd yr Undeb Ewropeaidd

Mae'r broses gaffael yn gysylltiedig â phrosiect a/neu raglen a ariennir gan gronfeydd yr Undeb Ewropeaidd: Na

Rhif y Lot 16

II.2.1) Teitl

Lot 16 Idarubicin Hydrochlioride Injection Powder For Reconstitution

II.2.2) Cod(au) CPV ychwanegol

33600000

II.2.3) Man cyflawni

Cod NUTS:

UKM


Prif safle neu fan cyflawni:

All entities constituted pursuant to the National Health Services (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to New Public Bodies (Joint Working) Scotland Act 2014

II.2.4) Disgrifiad o’r caffaeliad

Supply of Idarubicin Hydrochlioride Injection Powder For Reconstitution to NHS Scotland. The Authority intends awarding all presentations within this lot to a single supplier. Full details can be found within the ITT.

II.2.5) Meini prawf dyfarnu

Maen prawf isod:

Maes prawf ansawdd: Logistics / Pwysoliad: 5

Price / Pwysoliad:  95

II.2.6) Gwerth amcangyfrifedig

Gwerth heb gynnwys TAW: 28 000.00 GBP

II.2.7) Hyd y contract, y cytundeb fframwaith neu’r system brynu ddynamig

Hyd mewn misoedd: 24

Gall y contract hwn gael ei adnewyddu: Ydy

Disgrifiad o’r adnewyddiadau:

The Authority is entitled at its sole discretion to extend the Framework Agreement for up to a maximum of twenty four (24) months by giving a minimum of three (3) months written notice of such extension(s).

II.2.9) Gwybodaeth am y cyfyngiadau ar nifer yr ymgeiswyr a gaiff eu gwahodd

II.2.10) Gwybodaeth am amrywiadau

Derbynnir amrywiadau: Na

II.2.11) Gwybodaeth am opsiynau

Opsiynau: Na

II.2.13) Gwybodaeth am Gronfeydd yr Undeb Ewropeaidd

Mae'r broses gaffael yn gysylltiedig â phrosiect a/neu raglen a ariennir gan gronfeydd yr Undeb Ewropeaidd: Na

Rhif y Lot 17

II.2.1) Teitl

Lot 17 Ifosfamide Injection Powder For Reconstitution

II.2.2) Cod(au) CPV ychwanegol

33600000

II.2.3) Man cyflawni

Cod NUTS:

UKM


Prif safle neu fan cyflawni:

All entities constituted pursuant to the National Health Services (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to New Public Bodies (Joint Working) Scotland Act 2014.

II.2.4) Disgrifiad o’r caffaeliad

Supply of Ifosfamide Injection Powder For Reconstitution to NHS Scotland. The Authority intends awarding all presentations within this lot to a single supplier. Full details can be found within the ITT.

II.2.5) Meini prawf dyfarnu

Maen prawf isod:

Maes prawf ansawdd: Logistics / Pwysoliad: 5

Price / Pwysoliad:  95

II.2.6) Gwerth amcangyfrifedig

Gwerth heb gynnwys TAW: 2 721 676.00 GBP

II.2.7) Hyd y contract, y cytundeb fframwaith neu’r system brynu ddynamig

Hyd mewn misoedd: 24

Gall y contract hwn gael ei adnewyddu: Ydy

Disgrifiad o’r adnewyddiadau:

The Authority is entitled at its sole discretion to extend the Framework Agreement for up to a maximum of twenty four (24) months by giving a minimum of three (3) months written notice of such extension(s).

II.2.9) Gwybodaeth am y cyfyngiadau ar nifer yr ymgeiswyr a gaiff eu gwahodd

II.2.10) Gwybodaeth am amrywiadau

Derbynnir amrywiadau: Na

II.2.11) Gwybodaeth am opsiynau

Opsiynau: Na

II.2.13) Gwybodaeth am Gronfeydd yr Undeb Ewropeaidd

Mae'r broses gaffael yn gysylltiedig â phrosiect a/neu raglen a ariennir gan gronfeydd yr Undeb Ewropeaidd: Na

Rhif y Lot 18

II.2.1) Teitl

Lot 18 Irinotecan Hydrochloride Injection

II.2.2) Cod(au) CPV ychwanegol

33600000

II.2.3) Man cyflawni

Cod NUTS:

UKM


Prif safle neu fan cyflawni:

All entities constituted pursuant to the National Health Services (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to New Public Bodies (Joint Working) Scotland Act 2014

II.2.4) Disgrifiad o’r caffaeliad

Supply of Irinotecan Hydrochloride Injection to NHS Scotland. The Authority intends awarding all presentations within this lot to a single supplier. Full details can be found within the ITT.

II.2.5) Meini prawf dyfarnu

Maen prawf isod:

Maes prawf ansawdd: Logistics / Pwysoliad: 5

Price / Pwysoliad:  95

II.2.6) Gwerth amcangyfrifedig

Gwerth heb gynnwys TAW: 248 266.00 GBP

II.2.7) Hyd y contract, y cytundeb fframwaith neu’r system brynu ddynamig

Hyd mewn misoedd: 24

Gall y contract hwn gael ei adnewyddu: Ydy

Disgrifiad o’r adnewyddiadau:

The Authority is entitled at its sole discretion to extend the Framework Agreement for up to a maximum of twenty four (24) months by giving a minimum of three (3) months written notice of such extension(s).

II.2.9) Gwybodaeth am y cyfyngiadau ar nifer yr ymgeiswyr a gaiff eu gwahodd

II.2.10) Gwybodaeth am amrywiadau

Derbynnir amrywiadau: Na

II.2.11) Gwybodaeth am opsiynau

Opsiynau: Na

II.2.13) Gwybodaeth am Gronfeydd yr Undeb Ewropeaidd

Mae'r broses gaffael yn gysylltiedig â phrosiect a/neu raglen a ariennir gan gronfeydd yr Undeb Ewropeaidd: Na

Rhif y Lot 19

II.2.1) Teitl

Lot 19 Lanreotide Injection Prefilled Syringes

II.2.2) Cod(au) CPV ychwanegol

33600000

II.2.3) Man cyflawni

Cod NUTS:

UKM


Prif safle neu fan cyflawni:

All entities constituted pursuant to the National Health Services (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to New Public Bodies (Joint Working) Scotland Act 2014.

II.2.4) Disgrifiad o’r caffaeliad

Supply of Lanreotide Injection Prefilled Syringes to NHS Scotland. The Authority intends awarding all presentations within this lot to a single supplier. Full details can be found within the ITT.

II.2.5) Meini prawf dyfarnu

Maen prawf isod:

Maes prawf ansawdd: Logistics / Pwysoliad: 5

Price / Pwysoliad:  95

II.2.6) Gwerth amcangyfrifedig

Gwerth heb gynnwys TAW: 4 686 468.00 GBP

II.2.7) Hyd y contract, y cytundeb fframwaith neu’r system brynu ddynamig

Hyd mewn misoedd: 24

Gall y contract hwn gael ei adnewyddu: Ydy

Disgrifiad o’r adnewyddiadau:

The Authority is entitled at its sole discretion to extend the Framework Agreement for up to a maximum of twenty four (24) months by giving a minimum of three (3) months written notice of such extension(s).

II.2.9) Gwybodaeth am y cyfyngiadau ar nifer yr ymgeiswyr a gaiff eu gwahodd

II.2.10) Gwybodaeth am amrywiadau

Derbynnir amrywiadau: Na

II.2.11) Gwybodaeth am opsiynau

Opsiynau: Na

II.2.13) Gwybodaeth am Gronfeydd yr Undeb Ewropeaidd

Mae'r broses gaffael yn gysylltiedig â phrosiect a/neu raglen a ariennir gan gronfeydd yr Undeb Ewropeaidd: Na

Rhif y Lot 20

II.2.1) Teitl

Lot 20 Methotrexate Without Preservatives Injection

II.2.2) Cod(au) CPV ychwanegol

33600000

II.2.3) Man cyflawni

Cod NUTS:

UKM


Prif safle neu fan cyflawni:

All entities constituted pursuant to the National Health Services (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to New Public Bodies (Joint Working) Scotland Act 2014

II.2.4) Disgrifiad o’r caffaeliad

Supply of Methotrexate Without Preservatives Injection to NHS Scotland. The Authority intends awarding all presentations within this lot to a single supplier. Full details can be found within the ITT.

II.2.5) Meini prawf dyfarnu

Maen prawf isod:

Maes prawf ansawdd: Logistics / Pwysoliad: 5

Price / Pwysoliad:  95

II.2.6) Gwerth amcangyfrifedig

Gwerth heb gynnwys TAW: 304 589.00 GBP

II.2.7) Hyd y contract, y cytundeb fframwaith neu’r system brynu ddynamig

Hyd mewn misoedd: 24

Gall y contract hwn gael ei adnewyddu: Ydy

Disgrifiad o’r adnewyddiadau:

The Authority is entitled at its sole discretion to extend the Framework Agreement for up to a maximum of twenty four (24) months by giving a minimum of three (3) months written notice of such extension(s).

II.2.9) Gwybodaeth am y cyfyngiadau ar nifer yr ymgeiswyr a gaiff eu gwahodd

II.2.10) Gwybodaeth am amrywiadau

Derbynnir amrywiadau: Na

II.2.11) Gwybodaeth am opsiynau

Opsiynau: Na

II.2.13) Gwybodaeth am Gronfeydd yr Undeb Ewropeaidd

Mae'r broses gaffael yn gysylltiedig â phrosiect a/neu raglen a ariennir gan gronfeydd yr Undeb Ewropeaidd: Na

Rhif y Lot 21

II.2.1) Teitl

Lot 21 Methotrexate Oral Solution

II.2.2) Cod(au) CPV ychwanegol

33600000

II.2.3) Man cyflawni

Cod NUTS:

UKM


Prif safle neu fan cyflawni:

All entities constituted pursuant to the National Health Services (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to New Public Bodies (Joint Working) Scotland Act 2014

II.2.4) Disgrifiad o’r caffaeliad

Supply of Methotrexate Oral Solution to NHS Scotland. The Authority intends awarding all presentations within this lot to a single supplier. Full details can be found within the ITT.

II.2.5) Meini prawf dyfarnu

Maen prawf isod:

Maes prawf ansawdd: Logistics / Pwysoliad: 5

Price / Pwysoliad:  95

II.2.6) Gwerth amcangyfrifedig

Gwerth heb gynnwys TAW: 56 000.00 GBP

II.2.7) Hyd y contract, y cytundeb fframwaith neu’r system brynu ddynamig

Hyd mewn misoedd: 24

Gall y contract hwn gael ei adnewyddu: Ydy

Disgrifiad o’r adnewyddiadau:

The Authority is entitled at its sole discretion to extend the Framework Agreement for up to a maximum of twenty four (24) months by giving a minimum of three (3) months written notice of such extension(s).

II.2.9) Gwybodaeth am y cyfyngiadau ar nifer yr ymgeiswyr a gaiff eu gwahodd

II.2.10) Gwybodaeth am amrywiadau

Derbynnir amrywiadau: Na

II.2.11) Gwybodaeth am opsiynau

Opsiynau: Na

II.2.13) Gwybodaeth am Gronfeydd yr Undeb Ewropeaidd

Mae'r broses gaffael yn gysylltiedig â phrosiect a/neu raglen a ariennir gan gronfeydd yr Undeb Ewropeaidd: Na

Rhif y Lot 22

II.2.1) Teitl

Lot 22 Mitomycin Injection Powder For Reconstitution

II.2.2) Cod(au) CPV ychwanegol

33600000

II.2.3) Man cyflawni

Cod NUTS:

UKM


Prif safle neu fan cyflawni:

All entities constituted pursuant to the National Health Services (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to New Public Bodies (Joint Working) Scotland Act 2014.

II.2.4) Disgrifiad o’r caffaeliad

Supply of Mitomycin Injection Powder For Reconstitution to NHS Scotland. The Authority intends awarding all presentations within this lot to a single supplier. Full details can be found within the ITT.

II.2.5) Meini prawf dyfarnu

Maen prawf isod:

Maes prawf ansawdd: Logistics / Pwysoliad: 5

Price / Pwysoliad:  95

II.2.6) Gwerth amcangyfrifedig

Gwerth heb gynnwys TAW: 495 141.00 GBP

II.2.7) Hyd y contract, y cytundeb fframwaith neu’r system brynu ddynamig

Hyd mewn misoedd: 24

Gall y contract hwn gael ei adnewyddu: Ydy

Disgrifiad o’r adnewyddiadau:

The Authority is entitled at its sole discretion to extend the Framework Agreement for up to a maximum of twenty four (24) months by giving a minimum of three (3) months written notice of such extension(s).

II.2.9) Gwybodaeth am y cyfyngiadau ar nifer yr ymgeiswyr a gaiff eu gwahodd

II.2.10) Gwybodaeth am amrywiadau

Derbynnir amrywiadau: Na

II.2.11) Gwybodaeth am opsiynau

Opsiynau: Na

II.2.13) Gwybodaeth am Gronfeydd yr Undeb Ewropeaidd

Mae'r broses gaffael yn gysylltiedig â phrosiect a/neu raglen a ariennir gan gronfeydd yr Undeb Ewropeaidd: Na

Rhif y Lot 23

II.2.1) Teitl

Lot 23 Oxaliplatin Vial Solution

II.2.2) Cod(au) CPV ychwanegol

33600000

II.2.3) Man cyflawni

Cod NUTS:

UKM


Prif safle neu fan cyflawni:

All entities constituted pursuant to the National Health Services (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to New Public Bodies (Joint Working) Scotland Act 2014.

II.2.4) Disgrifiad o’r caffaeliad

Supply of Oxaliplatin Vial Solution to NHS Scotland. The Authority intends awarding all presentations within this lot to a single supplier. Full details can be found within the ITT.

II.2.5) Meini prawf dyfarnu

Maen prawf isod:

Maes prawf ansawdd: Logistics / Pwysoliad: 5

Price / Pwysoliad:  95

II.2.6) Gwerth amcangyfrifedig

Gwerth heb gynnwys TAW: 209 041.00 GBP

II.2.7) Hyd y contract, y cytundeb fframwaith neu’r system brynu ddynamig

Hyd mewn misoedd: 24

Gall y contract hwn gael ei adnewyddu: Ydy

Disgrifiad o’r adnewyddiadau:

The Authority is entitled at its sole discretion to extend the Framework Agreement for up to a maximum of twenty four (24) months by giving a minimum of three (3) months written notice of such extension(s).

II.2.9) Gwybodaeth am y cyfyngiadau ar nifer yr ymgeiswyr a gaiff eu gwahodd

II.2.10) Gwybodaeth am amrywiadau

Derbynnir amrywiadau: Na

II.2.11) Gwybodaeth am opsiynau

Opsiynau: Na

II.2.13) Gwybodaeth am Gronfeydd yr Undeb Ewropeaidd

Mae'r broses gaffael yn gysylltiedig â phrosiect a/neu raglen a ariennir gan gronfeydd yr Undeb Ewropeaidd: Na

Rhif y Lot 24

II.2.1) Teitl

Lot 24 Paclitaxel Concentrate For Intravenous Infusion

II.2.2) Cod(au) CPV ychwanegol

33600000

II.2.3) Man cyflawni

Cod NUTS:

UKM


Prif safle neu fan cyflawni:

All entities constituted pursuant to the National Health Services (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to New Public Bodies (Joint Working) Scotland Act 2014

II.2.4) Disgrifiad o’r caffaeliad

Supply of Paclitaxel Concentrate For Intravenous Infusion to NHS Scotland. The Authority intends awarding all presentations within this lot to a single supplier. Full details can be found within the ITT.

II.2.5) Meini prawf dyfarnu

Maen prawf isod:

Maes prawf ansawdd: Logistics / Pwysoliad: 5

Price / Pwysoliad:  95

II.2.6) Gwerth amcangyfrifedig

Gwerth heb gynnwys TAW: 406 689.00 GBP

II.2.7) Hyd y contract, y cytundeb fframwaith neu’r system brynu ddynamig

Hyd mewn misoedd: 24

Gall y contract hwn gael ei adnewyddu: Ydy

Disgrifiad o’r adnewyddiadau:

The Authority is entitled at its sole discretion to extend the Framework Agreement for up to a maximum of twenty four (24) months by giving a minimum of three (3) months written notice of such extension(s).

II.2.9) Gwybodaeth am y cyfyngiadau ar nifer yr ymgeiswyr a gaiff eu gwahodd

II.2.10) Gwybodaeth am amrywiadau

Derbynnir amrywiadau: Na

II.2.11) Gwybodaeth am opsiynau

Opsiynau: Na

II.2.13) Gwybodaeth am Gronfeydd yr Undeb Ewropeaidd

Mae'r broses gaffael yn gysylltiedig â phrosiect a/neu raglen a ariennir gan gronfeydd yr Undeb Ewropeaidd: Na

Rhif y Lot 25

II.2.1) Teitl

Lot 25 Temozolomide Capsules

II.2.2) Cod(au) CPV ychwanegol

33600000

II.2.3) Man cyflawni

Cod NUTS:

UKM


Prif safle neu fan cyflawni:

All entities constituted pursuant to the National Health Services (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to New Public Bodies (Joint Working) Scotland Act 2014

II.2.4) Disgrifiad o’r caffaeliad

Supply of Temozolomide Capsules to NHS Scotland. The Authority intends awarding all presentations within this lot to a single supplier. Full details can be found within the ITT.

II.2.5) Meini prawf dyfarnu

Maen prawf isod:

Maes prawf ansawdd: Logistics / Pwysoliad: 5

Price / Pwysoliad:  95

II.2.6) Gwerth amcangyfrifedig

Gwerth heb gynnwys TAW: 145 833.00 GBP

II.2.7) Hyd y contract, y cytundeb fframwaith neu’r system brynu ddynamig

Hyd mewn misoedd: 24

Gall y contract hwn gael ei adnewyddu: Ydy

Disgrifiad o’r adnewyddiadau:

The Authority is entitled at its sole discretion to extend the Framework Agreement for up to a maximum of twenty four (24) months by giving a minimum of three (3) months written notice of such extension(s).

II.2.9) Gwybodaeth am y cyfyngiadau ar nifer yr ymgeiswyr a gaiff eu gwahodd

II.2.10) Gwybodaeth am amrywiadau

Derbynnir amrywiadau: Na

II.2.11) Gwybodaeth am opsiynau

Opsiynau: Na

II.2.13) Gwybodaeth am Gronfeydd yr Undeb Ewropeaidd

Mae'r broses gaffael yn gysylltiedig â phrosiect a/neu raglen a ariennir gan gronfeydd yr Undeb Ewropeaidd: Na

Rhif y Lot 26

II.2.1) Teitl

Lot 26 Vincristine Without Preservatives Injection

II.2.2) Cod(au) CPV ychwanegol

33600000

II.2.3) Man cyflawni

Cod NUTS:

UKM


Prif safle neu fan cyflawni:

All entities constituted pursuant to the National Health Services (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to New Public Bodies (Joint Working) Scotland Act 2014.

II.2.4) Disgrifiad o’r caffaeliad

Supply of Vincristine Without Preservatives Injection to NHS Scotland. The Authority intends awarding all presentations within this lot to a single supplier. Full details can be found within the ITT.

II.2.5) Meini prawf dyfarnu

Maen prawf isod:

Maes prawf ansawdd: Logistics / Pwysoliad: 5

Price / Pwysoliad:  95

II.2.6) Gwerth amcangyfrifedig

Gwerth heb gynnwys TAW: 70 532.00 GBP

II.2.7) Hyd y contract, y cytundeb fframwaith neu’r system brynu ddynamig

Hyd mewn misoedd: 24

Gall y contract hwn gael ei adnewyddu: Ydy

Disgrifiad o’r adnewyddiadau:

The Authority is entitled at its sole discretion to extend the Framework Agreement for up to a maximum of twenty four (24) months by giving a minimum of three (3) months written notice of such extension(s).

II.2.9) Gwybodaeth am y cyfyngiadau ar nifer yr ymgeiswyr a gaiff eu gwahodd

II.2.10) Gwybodaeth am amrywiadau

Derbynnir amrywiadau: Na

II.2.11) Gwybodaeth am opsiynau

Opsiynau: Na

II.2.13) Gwybodaeth am Gronfeydd yr Undeb Ewropeaidd

Mae'r broses gaffael yn gysylltiedig â phrosiect a/neu raglen a ariennir gan gronfeydd yr Undeb Ewropeaidd: Na

Rhif y Lot 27

II.2.1) Teitl

Lot 27 Vinorelbine Injection

II.2.2) Cod(au) CPV ychwanegol

33600000

II.2.3) Man cyflawni

Cod NUTS:

UKM


Prif safle neu fan cyflawni:

All entities constituted pursuant to the National Health Services (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to New Public Bodies (Joint Working) Scotland Act 2014

II.2.4) Disgrifiad o’r caffaeliad

Supply of Vinorelbine Injections to NHS Scotland. The Authority intends awarding all presentations within this lot to a single supplier. Full details can be found within the ITT.

II.2.5) Meini prawf dyfarnu

Maen prawf isod:

Maes prawf ansawdd: Logistics / Pwysoliad: 5

Price / Pwysoliad:  95

II.2.6) Gwerth amcangyfrifedig

Gwerth heb gynnwys TAW: 54 400.00 GBP

II.2.7) Hyd y contract, y cytundeb fframwaith neu’r system brynu ddynamig

Hyd mewn misoedd: 24

Gall y contract hwn gael ei adnewyddu: Ydy

Disgrifiad o’r adnewyddiadau:

The Authority is entitled at its sole discretion to extend the Framework Agreement for up to a maximum of twenty four (24) months by giving a minimum of three (3) months written notice of such extension(s).

II.2.9) Gwybodaeth am y cyfyngiadau ar nifer yr ymgeiswyr a gaiff eu gwahodd

II.2.10) Gwybodaeth am amrywiadau

Derbynnir amrywiadau: Na

II.2.11) Gwybodaeth am opsiynau

Opsiynau: Na

II.2.13) Gwybodaeth am Gronfeydd yr Undeb Ewropeaidd

Mae'r broses gaffael yn gysylltiedig â phrosiect a/neu raglen a ariennir gan gronfeydd yr Undeb Ewropeaidd: Na

Rhif y Lot 28

II.2.1) Teitl

Lot 28 Aprepitant Capsules

II.2.2) Cod(au) CPV ychwanegol

33600000

II.2.3) Man cyflawni

Cod NUTS:

UKM


Prif safle neu fan cyflawni:

All entities constituted pursuant to the National Health Services (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to New Public Bodies (Joint Working) Scotland Act 2014

II.2.4) Disgrifiad o’r caffaeliad

Supply of Aprepitant Capsules to NHS Scotland. Each product line within this Lot will be grouped together and awarded to a single Framework Participant. Full details of Goods and volumes can be found within the ITT documents.

II.2.5) Meini prawf dyfarnu

Maen prawf isod:

Maes prawf ansawdd: Logistics / Pwysoliad: 5

Price / Pwysoliad:  95

II.2.6) Gwerth amcangyfrifedig

Gwerth heb gynnwys TAW: 116 097.00 GBP

II.2.7) Hyd y contract, y cytundeb fframwaith neu’r system brynu ddynamig

Hyd mewn misoedd: 24

Gall y contract hwn gael ei adnewyddu: Ydy

Disgrifiad o’r adnewyddiadau:

The Authority is entitled at its sole discretion to extend the Framework Agreement for up to a maximum of twenty four (24) months by giving a minimum of three (3) months written notice of such extension(s).

II.2.9) Gwybodaeth am y cyfyngiadau ar nifer yr ymgeiswyr a gaiff eu gwahodd

II.2.10) Gwybodaeth am amrywiadau

Derbynnir amrywiadau: Na

II.2.11) Gwybodaeth am opsiynau

Opsiynau: Na

II.2.13) Gwybodaeth am Gronfeydd yr Undeb Ewropeaidd

Mae'r broses gaffael yn gysylltiedig â phrosiect a/neu raglen a ariennir gan gronfeydd yr Undeb Ewropeaidd: Na

Rhif y Lot 29

II.2.1) Teitl

Lot 29 Topotecan Capsules

II.2.2) Cod(au) CPV ychwanegol

33600000

II.2.3) Man cyflawni

Cod NUTS:

UKM


Prif safle neu fan cyflawni:

All entities constituted pursuant to the National Health Services (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to New Public Bodies (Joint Working) Scotland Act 2014

II.2.4) Disgrifiad o’r caffaeliad

Supply of Topotecan Capsules to NHS Scotland. Each product line within this Lot will be grouped together and awarded to a single Framework Participant. Full details of Goods and volumes can be found within the ITT documents.

II.2.5) Meini prawf dyfarnu

Maen prawf isod:

Maes prawf ansawdd: Logistics / Pwysoliad: 5

Price / Pwysoliad:  95

II.2.6) Gwerth amcangyfrifedig

Gwerth heb gynnwys TAW: 123 900.00 GBP

II.2.7) Hyd y contract, y cytundeb fframwaith neu’r system brynu ddynamig

Hyd mewn misoedd: 24

Gall y contract hwn gael ei adnewyddu: Ydy

Disgrifiad o’r adnewyddiadau:

The Authority is entitled at its sole discretion to extend the Framework Agreement for up to a maximum of twenty four (24) months by giving a minimum of three (3) months written notice of such extension(s).

II.2.9) Gwybodaeth am y cyfyngiadau ar nifer yr ymgeiswyr a gaiff eu gwahodd

II.2.10) Gwybodaeth am amrywiadau

Derbynnir amrywiadau: Na

II.2.11) Gwybodaeth am opsiynau

Opsiynau: Na

II.2.13) Gwybodaeth am Gronfeydd yr Undeb Ewropeaidd

Mae'r broses gaffael yn gysylltiedig â phrosiect a/neu raglen a ariennir gan gronfeydd yr Undeb Ewropeaidd: Na

Rhif y Lot 30

II.2.1) Teitl

Lot 30 Topotecan Concentrate For Solution For Infusion

II.2.2) Cod(au) CPV ychwanegol

33600000

II.2.3) Man cyflawni

Cod NUTS:

UKM


Prif safle neu fan cyflawni:

All entities constituted pursuant to the National Health Services (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to New Public Bodies (Joint Working) Scotland Act 2014

II.2.4) Disgrifiad o’r caffaeliad

Supply of Topotecan Concentrate For Solution For Infusion to NHS Scotland. Each product line within this Lot will be grouped together and awarded to a single Framework Participant. Full details of Goods and volumes can be found within the ITT documents

II.2.5) Meini prawf dyfarnu

Maen prawf isod:

Maes prawf ansawdd: Logistics / Pwysoliad: 5

Price / Pwysoliad:  95

II.2.6) Gwerth amcangyfrifedig

Gwerth heb gynnwys TAW: 137 280.00 GBP

II.2.7) Hyd y contract, y cytundeb fframwaith neu’r system brynu ddynamig

Hyd mewn misoedd: 24

Gall y contract hwn gael ei adnewyddu: Ydy

Disgrifiad o’r adnewyddiadau:

The Authority is entitled at its sole discretion to extend the Framework Agreement for up to a maximum of twenty-four (24) months by giving a minimum of three (3) months written notice of such extension(s).

II.2.9) Gwybodaeth am y cyfyngiadau ar nifer yr ymgeiswyr a gaiff eu gwahodd

II.2.10) Gwybodaeth am amrywiadau

Derbynnir amrywiadau: Na

II.2.11) Gwybodaeth am opsiynau

Opsiynau: Na

II.2.13) Gwybodaeth am Gronfeydd yr Undeb Ewropeaidd

Mae'r broses gaffael yn gysylltiedig â phrosiect a/neu raglen a ariennir gan gronfeydd yr Undeb Ewropeaidd: Na

Rhif y Lot 31

II.2.1) Teitl

Lot 31 Octreotide Injection

II.2.2) Cod(au) CPV ychwanegol

33600000

II.2.3) Man cyflawni

Cod NUTS:

UKM


Prif safle neu fan cyflawni:

All entities constituted pursuant to the National Health Services (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to New Public Bodies (Joint Working) Scotland Act 2014

II.2.4) Disgrifiad o’r caffaeliad

Supply of Octreotide Injection. The Authority intends awarding all presentations within this lot to a single supplier. Full details of Goods and volumes can be found within the ITT documents.

II.2.5) Meini prawf dyfarnu

Maen prawf isod:

Maes prawf ansawdd: Logistics / Pwysoliad: 5

Price / Pwysoliad:  95

II.2.6) Gwerth amcangyfrifedig

Gwerth heb gynnwys TAW: 166 600.00 GBP

II.2.7) Hyd y contract, y cytundeb fframwaith neu’r system brynu ddynamig

Hyd mewn misoedd: 24

Gall y contract hwn gael ei adnewyddu: Ydy

Disgrifiad o’r adnewyddiadau:

The Authority is entitled at its sole discretion to extend the Framework Agreement for up to a maximum of twenty-four (24) months by giving a minimum of three (3) months written notice of such extension(s).

II.2.9) Gwybodaeth am y cyfyngiadau ar nifer yr ymgeiswyr a gaiff eu gwahodd

II.2.10) Gwybodaeth am amrywiadau

Derbynnir amrywiadau: Na

II.2.11) Gwybodaeth am opsiynau

Opsiynau: Na

II.2.13) Gwybodaeth am Gronfeydd yr Undeb Ewropeaidd

Mae'r broses gaffael yn gysylltiedig â phrosiect a/neu raglen a ariennir gan gronfeydd yr Undeb Ewropeaidd: Na

Rhif y Lot 32

II.2.1) Teitl

Lot 32 Filgrastim Pre-Filled Syringe

II.2.2) Cod(au) CPV ychwanegol

33600000

II.2.3) Man cyflawni

Cod NUTS:

UKM


Prif safle neu fan cyflawni:

All entities constituted pursuant to the National Health Services (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to New Public Bodies (Joint Working) Scotland Act 2014

II.2.4) Disgrifiad o’r caffaeliad

Supply of Filgrastim Pre-Filled Syringe to NHS Scotland in a range of presentations. The Authority intends awarding all presentations within this lot to a single supplier. Full details can be found within the ITT.

II.2.5) Meini prawf dyfarnu

Maen prawf isod:

Maes prawf ansawdd: Logistics / Pwysoliad: 5

Price / Pwysoliad:  95

II.2.6) Gwerth amcangyfrifedig

Gwerth heb gynnwys TAW: 1 606 575.00 GBP

II.2.7) Hyd y contract, y cytundeb fframwaith neu’r system brynu ddynamig

Hyd mewn misoedd: 24

Gall y contract hwn gael ei adnewyddu: Ydy

Disgrifiad o’r adnewyddiadau:

The Authority is entitled at its sole discretion to extend the Framework Agreement for up to a maximum of twenty-four (24) months by giving a minimum of three (3) months written notice of such extension(s).

II.2.9) Gwybodaeth am y cyfyngiadau ar nifer yr ymgeiswyr a gaiff eu gwahodd

II.2.10) Gwybodaeth am amrywiadau

Derbynnir amrywiadau: Na

II.2.11) Gwybodaeth am opsiynau

Opsiynau: Na

II.2.13) Gwybodaeth am Gronfeydd yr Undeb Ewropeaidd

Mae'r broses gaffael yn gysylltiedig â phrosiect a/neu raglen a ariennir gan gronfeydd yr Undeb Ewropeaidd: Na

Rhif y Lot 33

II.2.1) Teitl

Lot 33 Pemetrexed Powder For Solution For Infusion Vials

II.2.2) Cod(au) CPV ychwanegol

33600000

II.2.3) Man cyflawni

Cod NUTS:

UKM


Prif safle neu fan cyflawni:

All entities constituted pursuant to the National Health Services (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to New Public Bodies (Joint Working) Scotland Act 2014

II.2.4) Disgrifiad o’r caffaeliad

Supply of Pemetrexed Powder For Solution For Infusion Vials in various presentations to NHS Scotland.

The Authority intends to award this Lot as a single-supplier framework.

Full details of Goods and volumes can be found within the ITT documents.

II.2.5) Meini prawf dyfarnu

Maen prawf isod:

Maes prawf ansawdd: Logistics / Pwysoliad: 5

Price / Pwysoliad:  95

II.2.6) Gwerth amcangyfrifedig

Gwerth heb gynnwys TAW: 197 835.00 GBP

II.2.7) Hyd y contract, y cytundeb fframwaith neu’r system brynu ddynamig

Hyd mewn misoedd: 24

Gall y contract hwn gael ei adnewyddu: Ydy

Disgrifiad o’r adnewyddiadau:

The Authority is entitled at its sole discretion to extend the Framework Agreement for up to a maximum of twenty-four (24) months by giving a minimum of three (3) months written notice of such extension(s).

II.2.9) Gwybodaeth am y cyfyngiadau ar nifer yr ymgeiswyr a gaiff eu gwahodd

II.2.10) Gwybodaeth am amrywiadau

Derbynnir amrywiadau: Na

II.2.11) Gwybodaeth am opsiynau

Opsiynau: Na

II.2.13) Gwybodaeth am Gronfeydd yr Undeb Ewropeaidd

Mae'r broses gaffael yn gysylltiedig â phrosiect a/neu raglen a ariennir gan gronfeydd yr Undeb Ewropeaidd: Na

Rhif y Lot 34

II.2.1) Teitl

Lot 34 Pemetrexed (25Mg/Ml) Solution For Infusion Vials

II.2.2) Cod(au) CPV ychwanegol

33600000

II.2.3) Man cyflawni

Cod NUTS:

UKM


Prif safle neu fan cyflawni:

All entities constituted pursuant to the National Health Services (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to New Public Bodies (Joint Working) Scotland Act 2014

II.2.4) Disgrifiad o’r caffaeliad

Supply of Pemetrexed (25Mg/Ml) Solution For Infusion Vials to NHS Scotland in a range of presentations.

The Authority intends awarding all presentations within this lot to a single supplier.

Full details can be found within the ITT.

II.2.5) Meini prawf dyfarnu

Maen prawf isod:

Maes prawf ansawdd: Logistics / Pwysoliad: 5

Price / Pwysoliad:  95

II.2.6) Gwerth amcangyfrifedig

Gwerth heb gynnwys TAW: 211 832.00 GBP

II.2.7) Hyd y contract, y cytundeb fframwaith neu’r system brynu ddynamig

Hyd mewn misoedd: 24

Gall y contract hwn gael ei adnewyddu: Ydy

Disgrifiad o’r adnewyddiadau:

The Authority is entitled at its sole discretion to extend the Framework Agreement for up to a maximum of twenty-four (24) months by giving a minimum of three (3) months written notice of such extension(s).

II.2.9) Gwybodaeth am y cyfyngiadau ar nifer yr ymgeiswyr a gaiff eu gwahodd

II.2.10) Gwybodaeth am amrywiadau

Derbynnir amrywiadau: Na

II.2.11) Gwybodaeth am opsiynau

Opsiynau: Na

II.2.13) Gwybodaeth am Gronfeydd yr Undeb Ewropeaidd

Mae'r broses gaffael yn gysylltiedig â phrosiect a/neu raglen a ariennir gan gronfeydd yr Undeb Ewropeaidd: Na

Rhif y Lot 35

II.2.1) Teitl

Lot 35 Octreotide Vials Long Acting (Excluding Homecare)

II.2.2) Cod(au) CPV ychwanegol

33600000

II.2.3) Man cyflawni

Cod NUTS:

UKM


Prif safle neu fan cyflawni:

All entities constituted pursuant to the National Health Services (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to New Public Bodies (Joint Working) Scotland Act 2014

II.2.4) Disgrifiad o’r caffaeliad

Supply of Octreotide Vials Long Acting (Excluding Homecare) to NHS Scotland. The Authority intends awarding each product line as a multi-supplier unranked framework agreement and it is envisaged a maximum of 3 Suppliers will be awarded.

II.2.5) Meini prawf dyfarnu

Maen prawf isod:

Maes prawf ansawdd: Logistics / Pwysoliad: 5

Price / Pwysoliad:  95

II.2.6) Gwerth amcangyfrifedig

Gwerth heb gynnwys TAW: 220 850.00 GBP

II.2.7) Hyd y contract, y cytundeb fframwaith neu’r system brynu ddynamig

Hyd mewn misoedd: 24

Gall y contract hwn gael ei adnewyddu: Ydy

Disgrifiad o’r adnewyddiadau:

he Authority is entitled at its sole discretion to extend the Framework Agreement for up to a maximum of twenty-four (24) months by giving a minimum of three (3) months written notice of such extension(s).

II.2.9) Gwybodaeth am y cyfyngiadau ar nifer yr ymgeiswyr a gaiff eu gwahodd

II.2.10) Gwybodaeth am amrywiadau

Derbynnir amrywiadau: Na

II.2.11) Gwybodaeth am opsiynau

Opsiynau: Na

II.2.13) Gwybodaeth am Gronfeydd yr Undeb Ewropeaidd

Mae'r broses gaffael yn gysylltiedig â phrosiect a/neu raglen a ariennir gan gronfeydd yr Undeb Ewropeaidd: Na

Rhif y Lot 36

II.2.1) Teitl

Lot 36 Octreotide Vials Long Acting (Including Homecare)

II.2.2) Cod(au) CPV ychwanegol

33600000

II.2.3) Man cyflawni

Cod NUTS:

UKM


Prif safle neu fan cyflawni:

All entities constituted pursuant to the National Health Services (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to New Public Bodies (Joint Working) Scotland Act 2014

II.2.4) Disgrifiad o’r caffaeliad

Supply of Octreotide Vials Long Acting (Including Homecare) to NHS Scotland. The Authority intends awarding each product line as a multi-supplier unranked framework agreement and it is envisaged a maximum of 3 Suppliers will be awarded. Full details can be found within the ITT.

II.2.5) Meini prawf dyfarnu

Maen prawf isod:

Maes prawf ansawdd: Logistics / Pwysoliad: 5

Price / Pwysoliad:  95

II.2.6) Gwerth amcangyfrifedig

Gwerth heb gynnwys TAW: 1 514 152.00 GBP

II.2.7) Hyd y contract, y cytundeb fframwaith neu’r system brynu ddynamig

Hyd mewn misoedd: 24

Gall y contract hwn gael ei adnewyddu: Ydy

Disgrifiad o’r adnewyddiadau:

The Authority is entitled at its sole discretion to extend the Framework Agreement for up to a maximum of twenty-four (24) months by giving a minimum of three (3) months written notice of such extension(s).

II.2.9) Gwybodaeth am y cyfyngiadau ar nifer yr ymgeiswyr a gaiff eu gwahodd

II.2.10) Gwybodaeth am amrywiadau

Derbynnir amrywiadau: Na

II.2.11) Gwybodaeth am opsiynau

Opsiynau: Na

II.2.13) Gwybodaeth am Gronfeydd yr Undeb Ewropeaidd

Mae'r broses gaffael yn gysylltiedig â phrosiect a/neu raglen a ariennir gan gronfeydd yr Undeb Ewropeaidd: Na

Rhif y Lot 37

II.2.1) Teitl

Lot 37 Etoposide Injection

II.2.2) Cod(au) CPV ychwanegol

33600000

II.2.3) Man cyflawni

Cod NUTS:

UKM


Prif safle neu fan cyflawni:

All entities constituted pursuant to the National Health Services (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to New Public Bodies (Joint Working) Scotland Act 2014

II.2.4) Disgrifiad o’r caffaeliad

Supply of Etoposide Injection to NHS Scotland. The Authority intends to award this Lot as a ranked multi-supplier framework to a maximum of three (3) Framework Participants. Full details of Goods and volumes can be found within the ITT documents.

II.2.5) Meini prawf dyfarnu

Maen prawf isod:

Maes prawf ansawdd: Logistics / Pwysoliad: 5

Price / Pwysoliad:  95

II.2.6) Gwerth amcangyfrifedig

Gwerth heb gynnwys TAW: 167 904.00 GBP

II.2.7) Hyd y contract, y cytundeb fframwaith neu’r system brynu ddynamig

Hyd mewn misoedd: 24

Gall y contract hwn gael ei adnewyddu: Ydy

Disgrifiad o’r adnewyddiadau:

The Authority is entitled at its sole discretion to extend the Framework Agreement for up to a maximum of twenty-four (24) months by giving a minimum of three (3) months written notice of such extension(s).

II.2.9) Gwybodaeth am y cyfyngiadau ar nifer yr ymgeiswyr a gaiff eu gwahodd

II.2.10) Gwybodaeth am amrywiadau

Derbynnir amrywiadau: Na

II.2.11) Gwybodaeth am opsiynau

Opsiynau: Na

II.2.13) Gwybodaeth am Gronfeydd yr Undeb Ewropeaidd

Mae'r broses gaffael yn gysylltiedig â phrosiect a/neu raglen a ariennir gan gronfeydd yr Undeb Ewropeaidd: Na

Rhif y Lot 38

II.2.1) Teitl

Lot 38 Dasatinib Tablets

II.2.2) Cod(au) CPV ychwanegol

33600000

II.2.3) Man cyflawni

Cod NUTS:

UKM


Prif safle neu fan cyflawni:

All entities constituted pursuant to the National Health Services (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to New Public Bodies (Joint Working) Scotland Act 2014

II.2.4) Disgrifiad o’r caffaeliad

Supply of Dasatinib Tablets to NHS Scotland. The Authority intends awarding each product line as a multi-supplier ranked framework agreement and it is envisaged a maximum of 3 Suppliers will be awarded. Full details of Goods and volumes can be found within the ITT documents.

II.2.5) Meini prawf dyfarnu

Maen prawf isod:

Maes prawf ansawdd: Logistics / Pwysoliad: 5

Price / Pwysoliad:  95

II.2.6) Gwerth amcangyfrifedig

Gwerth heb gynnwys TAW: 143 280.00 GBP

II.2.7) Hyd y contract, y cytundeb fframwaith neu’r system brynu ddynamig

Hyd mewn misoedd: 24

Gall y contract hwn gael ei adnewyddu: Ydy

Disgrifiad o’r adnewyddiadau:

The Authority is entitled at its sole discretion to extend the Framework Agreement for up to a maximum of twenty-four (24) months by giving a minimum of three (3) months written notice of such extension(s).

II.2.9) Gwybodaeth am y cyfyngiadau ar nifer yr ymgeiswyr a gaiff eu gwahodd

II.2.10) Gwybodaeth am amrywiadau

Derbynnir amrywiadau: Na

II.2.11) Gwybodaeth am opsiynau

Opsiynau: Na

II.2.13) Gwybodaeth am Gronfeydd yr Undeb Ewropeaidd

Mae'r broses gaffael yn gysylltiedig â phrosiect a/neu raglen a ariennir gan gronfeydd yr Undeb Ewropeaidd: Na

Rhif y Lot 39

II.2.1) Teitl

Lot 39 Unranked Multi-Supplier Generic & Biosimilar Medicines

II.2.2) Cod(au) CPV ychwanegol

33600000

II.2.3) Man cyflawni

Cod NUTS:

UKM


Prif safle neu fan cyflawni:

All entities constituted pursuant to the National Health Services (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to New Public Bodies (Joint Working) Scotland Act 2014

II.2.4) Disgrifiad o’r caffaeliad

Supply of a number of Generic & Biosimilar Medicines including bevacizumab solution for infusion, doxorubicin liposomal solution for infusion, rituximab solution for infusion, trastuzumab powder for solution for infusion, sorafenib tablets and thalidomide capsules to NHS Scotland.

Each product line will be treated as an individual Lot and awarded as a unranked multi-supplier to an envisaged maximum of 6 Framework Participants.

Full details of Goods and volumes can be found within the ITT documents.

II.2.5) Meini prawf dyfarnu

Maen prawf isod:

Maes prawf ansawdd: Logistics / Pwysoliad: 5

Price / Pwysoliad:  95

II.2.6) Gwerth amcangyfrifedig

Gwerth heb gynnwys TAW: 10 529 050.00 GBP

II.2.7) Hyd y contract, y cytundeb fframwaith neu’r system brynu ddynamig

Hyd mewn misoedd: 24

Gall y contract hwn gael ei adnewyddu: Ydy

Disgrifiad o’r adnewyddiadau:

The Authority is entitled at its sole discretion to extend the Framework Agreement for up to a maximum of twenty-four (24) months by giving a minimum of three (3) months written notice of such extension(s).

II.2.9) Gwybodaeth am y cyfyngiadau ar nifer yr ymgeiswyr a gaiff eu gwahodd

II.2.10) Gwybodaeth am amrywiadau

Derbynnir amrywiadau: Na

II.2.11) Gwybodaeth am opsiynau

Opsiynau: Na

II.2.13) Gwybodaeth am Gronfeydd yr Undeb Ewropeaidd

Mae'r broses gaffael yn gysylltiedig â phrosiect a/neu raglen a ariennir gan gronfeydd yr Undeb Ewropeaidd: Na

Rhif y Lot 40

II.2.1) Teitl

Lot 40 Idarubicin Hydrochloride Solution for Infusion

II.2.2) Cod(au) CPV ychwanegol

33600000

II.2.3) Man cyflawni

Cod NUTS:

UKM

II.2.4) Disgrifiad o’r caffaeliad

Supply of Idarubicin Hydrochloride Solution for Infusion.

The Authority intends awarding all presentations within this lot to a single supplier.

Full details of Goods and volumes can be found within the ITT documents.

II.2.5) Meini prawf dyfarnu

Maen prawf isod:

Maes prawf ansawdd: Logistics / Pwysoliad: 5

Price / Pwysoliad:  95

II.2.6) Gwerth amcangyfrifedig

Gwerth heb gynnwys TAW: 13 114.00 GBP

II.2.7) Hyd y contract, y cytundeb fframwaith neu’r system brynu ddynamig

Hyd mewn misoedd: 24

Gall y contract hwn gael ei adnewyddu: Ydy

Disgrifiad o’r adnewyddiadau:

The Authority is entitled at its sole discretion to extend the Framework Agreement for up to a maximum of twenty-four (24) months by giving a minimum of three (3) months written notice of such extension(s).

II.2.9) Gwybodaeth am y cyfyngiadau ar nifer yr ymgeiswyr a gaiff eu gwahodd

II.2.10) Gwybodaeth am amrywiadau

Derbynnir amrywiadau: Na

II.2.11) Gwybodaeth am opsiynau

Opsiynau: Na

II.2.13) Gwybodaeth am Gronfeydd yr Undeb Ewropeaidd

Mae'r broses gaffael yn gysylltiedig â phrosiect a/neu raglen a ariennir gan gronfeydd yr Undeb Ewropeaidd: Na

Rhif y Lot 41

II.2.1) Teitl

Lot 41 Single Supplier Generic Medicines

II.2.2) Cod(au) CPV ychwanegol

33600000

II.2.3) Man cyflawni

Cod NUTS:

UKM

II.2.4) Disgrifiad o’r caffaeliad

Supply of a range of generic cancer medicines to NHS Scotland. Each product line will be treated as an individual Lot and awarded to a single Framework Participant.

Full details of Goods and volumes can be found within the ITT documents.

II.2.5) Meini prawf dyfarnu

Maen prawf isod:

Maes prawf ansawdd: Logistics / Pwysoliad: 5

Price / Pwysoliad:  95

II.2.6) Gwerth amcangyfrifedig

Gwerth heb gynnwys TAW: 30 448 391.00 GBP

II.2.7) Hyd y contract, y cytundeb fframwaith neu’r system brynu ddynamig

Hyd mewn misoedd: 24

Gall y contract hwn gael ei adnewyddu: Ydy

Disgrifiad o’r adnewyddiadau:

The Authority is entitled at its sole discretion to extend the Framework Agreement for up to a maximum of twenty-four (24) months by giving a minimum of three (3) months written notice of such extension(s).

II.2.9) Gwybodaeth am y cyfyngiadau ar nifer yr ymgeiswyr a gaiff eu gwahodd

II.2.10) Gwybodaeth am amrywiadau

Derbynnir amrywiadau: Na

II.2.11) Gwybodaeth am opsiynau

Opsiynau: Na

II.2.13) Gwybodaeth am Gronfeydd yr Undeb Ewropeaidd

Mae'r broses gaffael yn gysylltiedig â phrosiect a/neu raglen a ariennir gan gronfeydd yr Undeb Ewropeaidd: Na

Section III: Gwybodaeth gyfreithiol, economaidd, ariannol a thechnegol

III.1) Amodau ar gyfer cymryd rhan

III.1.3) Gallu technegol a phroffesiynol

Rhestr a disgrifiad byr o’r meini prawf dethol:

(a) Potential Framework Participants must be able to demonstrate the existence of a valid and current UK Marketing Authorisation (PL, PLGB or PLPI number) that has been approved by the MHRA for all tendered Medicines at the date of submission of the tender.

(b) Potential Framework Participants and any sub-contractor(s) must possess valid certification of BS EN ISO 9001 or equivalent.

(c) All tendered Goods must comply with the MHRA best Practice Guidance on Labelling and Packaging and the National Patient Safety Agency ("NPSA") Guidelines on Packaging and Labelling on pack design.

(d) Potential Framework Participants are required to provide evidence that their organisation has taken steps to build their awareness of the climate change emergency and how they will respond.


Lefel(au) gofynnol y safonau sydd eu hangen:

a) Confirmation of existence of a valid and current UK Marketing Authorisation (PL, PLGB or PLPI number) that has been approved by the MHRA for all tendered Medicines at the date of submission of the tender should be included in the Qualification Envelope of the ITT under the Technical and Professional ability: Quality Control.

(b) Confirmation of the existence of valid certification of BS EN ISO 9001 or equivalent. Confirmation of such certification should be included in the Qualification Envelope of the ITT under the Quality Assurance Schemes.

(c) Confirmation that samples for tendered Goods will be supplied upon request to ensure compliance with the MHRA best Practice Guidance on Labelling and Packaging and the National Patient Safety Agency ("NPSA") Guidelines on Packaging and Labelling on pack design. Confirmation of sample provision should be provided in the Qualification Envelope of the ITT under Technical and Professional ability: Products.

(d) A completed copy of the Bidder Climate Change Plan Template, including planned projects and actions to reduce the bidder’s carbon emissions should be provided in the Qualification Envelope of the ITT under Environmental Management Criteria. This does not need to contain calculated carbon emissions.

III.2) Amodau sy’n gysylltiedig â’r contract

Section IV: Gweithdrefn

IV.1) Disgrifiad

IV.1.1) Y math o weithdrefn

Gweithdrefn agored

IV.1.3) Gwybodaeth am gytundeb fframwaith neu system brynu ddynamig

The procurement involves the establishment of a framework agreement with several operators.

IV.1.8) Gwybodaeth am Gytundeb Caffael y Llywodraeth (GPA)

The procurement is covered by the Government Procurement Agreement: Ydy

IV.2) Gwybodaeth weinyddol

IV.2.2) Terfyn amser i dendrau neu geisiadau i gymryd rhan ddod i law

Dyddiad: 17/10/2022

Amser lleol: 12:00

IV.2.4) Ym mha iaith/ieithoedd y gellir cyflwyno tendrau neu geisiadau i gymryd rhan

EN

IV.2.6) Yr isafswm cyfnod gofynnol i’r sawl sy’n tendro gynnal y tendr

Hyd mewn misoedd: 3  (o’r dyddiad a nodwyd i dendr ddod i law)

IV.2.7) Amodau ar gyfer agor tendrau

Dyddiad: 17/10/2022

Amser lleol: 12:00

Section VI: Gwybodaeth ategol

VI.1) Gwybodaeth am ailddigwydd

Caffaeliad cylchol yw hwn: Na

VI.2) Gwybodaeth am lifau gwaith electronig

Defnyddir archebion electronig

Derbynnir anfonebau electronig

Defnyddir taliadau electronig

VI.3) Gwybodaeth ychwanegol

The estimated value referred to in Section II.I.5 and within each Lot covers the twenty-four (24) months contract duration and the full twenty-four (24) months extension options.

The buyer is using PCS-Tender to conduct this ITT exercise. The Project code is 22063. For more information see: http://www.publiccontractsscotland.gov.uk/info/InfoCentre.aspx?ID=2343

A sub-contract clause has been included in this contract. For more information see: http://www.publiccontractsscotland.gov.uk/info/InfoCentre.aspx?ID=2363

Community benefits are included in this requirement. For more information see: https://www.gov.scot/policies/public-sector-procurement/community-benefits-in-procurement/

A summary of the expected community benefits has been provided as follows:

It is a mandatory requirement that Potential Framework Participants agree to support the concept, provision and ongoing development of community benefits provision in relation to this framework.

Potential Framework Participants are required to agree to this mandatory requirement. They are also requested to provide a brief summary of the community benefits that have recently been delivered within Scotland, if at all, and also what impact and outcomes these have achieved.

Potential Framework Participants are required to summarise any proposed community benefits that will be developed and delivered as part of this contract if successful or, alternatively, Potential Framework Participants confirm that they will engage with the NHS Scotland’s Community Benefits Gateway (CBG). This gateway, developed through requests from suppliers seeking opportunities to support the delivery of community benefits within the contracting region, provides information on community benefit opportunities. The CBG is a free and easy to use online service that connects NHS Scotland suppliers with third sector community organisations within Scotland and will be used for tracking and reporting and is an approved compliant route to the realisation of community benefits.

For further information please visit www.nss.nhs.scot/procurement-and-logistics/sustainability/access-our-community-benefit-gateway

(SC Ref:705779)

VI.4) Gweithdrefnau adolygu

VI.4.1) Corff adolygu

Edinburgh Sheriff Court

Sheriff Court House, 27 Chambers Street

Edinburgh

EH1 1LB

UK

Ffôn: +44 1312252525

E-bost: edinburgh@scotcourts.gov.uk

Cyfeiriad(au) rhyngrwyd

URL: https://www.scotcourts.gov.uk/the-courts/court-locations/edinburgh-sheriff-court-and-justice-of-the-peace-court

VI.4.3) Gweithdrefn adolygu

Gwybodaeth fanwl gywir am y terfyn(au) amser ar gyfer gweithdrefnau adolygu:

The Authority will notify economic operators who submitted a tender or (where no deselection notification has previously been made) applied to be selected to tender, of its decision to award the framework agreement which notification will contain among other information, a summary of the reasons why the economic operator was unsuccessful. The notification will incorporate a 'standstill period' of a minimum of 10 clear calendar days (or a minimum of 15 if the communication method used is not electronic) between the date on which the Authority despatches the notice(s) and the date on which the Authority proposes to conclude the relevant framework agreement. The bringing of court proceedings against the Authority during the standstill period will automatically continue the prohibition on entering into the framework agreement until the court proceedings are determined, discontinued or disposed of, or the court, by interim order, brings to an end the prohibition. The remedies that may be awarded by the courts before the framework agreement has been entered into include the setting aside of the decision to award the framework agreement to the winning tenderer(s). The bringing of court proceedings against the Authority after the framework agreement has been entered into will not affect the framework agreement unless grounds for the imposition of special penalties under the Public Contracts (Scotland) Regulations 2015 can be established. Otherwise the remedies that may be awarded by the courts where the framework agreement has been entered into are limited to the award of damages.

VI.5) Dyddiad anfon yr hysbysiad hwn

16/09/2022

Codio

Categorïau nwyddau

ID Teitl Prif gategori
33600000 Cynhyrchion fferyllol Cyfarpar meddygol, deunydd fferyllol a chynhyrchion gofal personol

Lleoliadau Dosbarthu

ID Disgrifiad
100 DU - I gyd

Cyfyngiadau Rhanbarthol ar y Rhybuddion

Mae’r prynwr wedi cyfyngu’r rhybuddion ar gyfer yr hysbysiad hwn i gyflenwyr yn y rhanbarthau canlynol.

ID Disgrifiad
Nid oes cyfyngiadau ar y rhybuddion ar gyfer yr hysbysiad hwn.

Ynglŷn â'r prynwr

Prif gyswllt:
Linda.Downie3@nhs.scot
Cyswllt gweinyddol:
N/a
Cyswllt technegol:
N/a
Cyswllt arall:
N/a

Gwybodaeth bellach

Dyddiad Manylion
Nid oes unrhyw wybodaeth bellach wedi'i lanlwytho.

0800 222 9004

Mae'r llinellau ar agor rhwng 8:30am a 5pm o ddydd Llun i ddydd Gwener.

Rydym yn croesawu galwadau'n Gymraeg.

We welcome calls in Welsh.